Fractyl Health, Inc. GUTS 深 沪

Fractyl Health's Revita Procedure Helps Patients Keep Weight Off After Stopping GLP-1 Drugs

Fractyl Health (NASDAQ: GUTS) released positive 6-month results from its REVEAL-1 study in obese patients who discontinued GLP-1 therapy.

12-03 01:28

Preview: Fractyl Health's Earnings

Fractyl Health (NASDAQ:GUTS) will release its quarterly earnings report on Wedn...

11-12 01:12

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Revita procedure showed promising results in maintaining or reducing weight after discontinuing GLP-1 therapy, with 12 out of 13 participants maintaining or losing weight at 3 months. No serious adverse effects were reported, and weight regain was significantly lower than expected.

06-23 11:40

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Fractyl Health获得两项新专利，进一步巩固了其在十二指肠再表面化技术领域的领导地位，新专利涉及使用热能和非热能电能的组织消融系统，两项专利的发布加强了公司针对代谢疾病治疗的知识产权布局，同时也为Revita产品的临床数据发布做好准备。

06-18 11:00

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Fractyl Health将展示其Rejuva Smart GLP-1胰腺基因疗法平台的新临床前数据，该数据将于6月22日在美国糖尿病协会科学会议上以海报形式呈现。Rejuva平台旨在通过基因治疗对抗肥胖和2型糖尿病。

06-13 11:00

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

06-04 11:00